118 related articles for article (PubMed ID: 15020354)
21. Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option.
Tausche AK; Richter K; Grässler A; Hänsel S; Roch B; Schröder HE
Ann Rheum Dis; 2004 Oct; 63(10):1351-2. PubMed ID: 15361402
[No Abstract] [Full Text] [Related]
22. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.
Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM
Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195
[TBL] [Abstract][Full Text] [Related]
23. Diverse effects of infliximab and etanercept on T lymphocytes.
Sieper J; Van Den Brande J
Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):23-7. PubMed ID: 15852251
[TBL] [Abstract][Full Text] [Related]
24. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.
Stojanov S; Dejaco C; Lohse P; Huss K; Duftner C; Belohradsky BH; Herold M; Schirmer M
Ann Rheum Dis; 2008 Sep; 67(9):1292-8. PubMed ID: 18180277
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of pemphigus vulgaris with etanercept in four patients.
Shetty A; Marcum CB; Glass LF; Carter JD
J Drugs Dermatol; 2009 Oct; 8(10):940-3. PubMed ID: 19852124
[TBL] [Abstract][Full Text] [Related]
26. Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by tumour necrosis factor-alpha inhibition.
Wachter T; Murach WM; Bröcker EB; Schön MP
Br J Dermatol; 2007 Sep; 157(3):627-9. PubMed ID: 17596151
[No Abstract] [Full Text] [Related]
27. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome.
Quillinan N; Mannion G; Mohammad A; Coughlan R; Dickie LJ; McDermott MF; McGonagle D
Ann Rheum Dis; 2011 Sep; 70(9):1692-3. PubMed ID: 21378401
[No Abstract] [Full Text] [Related]
28. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
29. Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases.
Langford CA
Nat Clin Pract Rheumatol; 2008 Jul; 4(7):364-70. PubMed ID: 18506159
[TBL] [Abstract][Full Text] [Related]
30. Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected].
Cortis E; De Benedetti F; Insalaco A; Cioschi S; Muratori F; D'Urbano LE; Ugazio AG
J Pediatr; 2004 Dec; 145(6):851-5. PubMed ID: 15580218
[TBL] [Abstract][Full Text] [Related]
31. [Usefulness of non-steroidal anti-inflammatory agents in the treatment of temporal arteritis].
González-Gay MA; Alonso MD; Agüero JJ; Sánchez-Andrade A
Med Clin (Barc); 1992 Oct; 99(10):397. PubMed ID: 1460890
[No Abstract] [Full Text] [Related]
32. Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al.
Olivieri I; Padula A; Scarano E
Arthritis Rheum; 2002 Dec; 46(12):3396-8; author reply 3398. PubMed ID: 12483753
[No Abstract] [Full Text] [Related]
33. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
Krishnan R; Cella D; Leonardi C; Papp K; Gottlieb AB; Dunn M; Chiou CF; Patel V; Jahreis A
Br J Dermatol; 2007 Dec; 157(6):1275-7. PubMed ID: 17916204
[No Abstract] [Full Text] [Related]
34. Etanercept treatment in the endotoxin-induced uveitis of rats.
Avunduk MC; Avunduk AM; Oztekin E; Baltaci AK; Ozyazgan Y; Mogolkoc R
Exp Eye Res; 2004 Sep; 79(3):357-65. PubMed ID: 15336498
[TBL] [Abstract][Full Text] [Related]
35. [Anti-TNF alfa therapy in ankylosing spondylitis].
Cravo AR; Tavares V; Da Silva JC
Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
[TBL] [Abstract][Full Text] [Related]
36. The medical uses and side effects of etanercept with a focus on cutaneous disease.
Scheinfeld N
J Drugs Dermatol; 2004; 3(6):653-9. PubMed ID: 15624748
[TBL] [Abstract][Full Text] [Related]
37. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
38. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
39. Pyoderma vegetans associated with severe psoriatic arthritis: good response to etanercept.
Carrera C; Mascaró JM; Moreno-Romero JA; Iranzo P; Palou J; Zamora E; Herrero C
Dermatology; 2007; 214(1):77-81. PubMed ID: 17191052
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.
Baraliakos X; Davis J; Tsuji W; Braun J
Arthritis Rheum; 2005 Apr; 52(4):1216-23. PubMed ID: 15818694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
